The U.S. Health Resources and Services Administration yesterday referred drug manufacturer Merck to the Department of Health and Human Services Office of Inspector General for possible imposition of civil fines over Merck’s 340B contract pharmacy restrictions.
Public Health Services Lt. Cmdr. Emeka Egwim, Director of HRSA’s Office of Pharmacy Affairs, sent Merck a letter yesterday notifying it about the referral to OIG. Merck did not immediately respond to a request for comment.
The U.S. Health Resources and Services Administration yesterday referred drug manufacturer Merck to the Department of Health and Human Services Office of Inspector General for possible imposition of civil fines over Merck’s 340B contract pharmacy restrictions.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.